Employment of Programmed Cell Death in Therapeutics: How Well Can We Utilize the Nemesis?
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 241
Special Issue Editors
2. Department of Laboratory Medicine, University of California, San Fransisco, CA 94143, USA
Interests: apoptosis; cancer therapeutics; mechanisms of cell death; EMT; metastasis; solid tumors; therapeutic resistance
Interests: cell culture; immunofluorescence; flow cytometry; gene expression; western blot analysis; cell signaling; cancer biology; apoptosis; cancer cell biology; in vitro cell culture
Special Issue Information
Dear Colleagues,
Malfunctions in apoptosis are implicated in numerous illnesses, including autoimmune diseases linked to dysregulated programmed cell death. A wide array of research on apoptosis will not only aid in understanding the fundamental process, but also improve disease therapeutics research. Drugs and therapeutic measures designed based on the current understanding of apoptosis have long been employed, and several small molecule apoptosis inducers and inhibitors have been clinically employed for eliminating morbid cells, and therefore, treating diseases such as cancer, Parkinson’s, etc.
Since apoptosis is a highly coordinated process, its specificity and nature will answer many questions pertaining to the diseases; it is encouraging that drugs that block or promote apoptotic body formation have been advanced to the translational stage. Therefore, therapies and drugs designed based on the regulation of programmed cell death and apoptotic body formation hold great promises of curing intractable diseases, and they also serve as adjuvant candidates in resistant cancers.
Dr. Rohit Gundamaraju
Prof. Dr. Young Ho Kim
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- apoptosis
- cancer therapeutics
- mechanisms of cell death
